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Abstract
High-density lipoproteins (HDLs) exert many beneficial effects which may help
to protect against the development or progression of atherosclerosis or even
facilitate lesion regression. These activities include promoting cellular choles-
terol efflux, protecting low-density lipoproteins (LDLs) from modification,
preserving endothelial function, as well as anti-inflammatory and antithrombotic
effects. However, questions remain about the relative importance of these
activities for atheroprotection. Furthermore, the many molecules (both lipids
and proteins) associated with HDLs exert both distinct and overlapping
activities, which may be compromised by inflammatory conditions, resulting
in either loss of function or even gain of dysfunction. This complexity of HDL
functionality has so far precluded elucidation of distinct structure–function
relationships for HDL or its components. A better understanding of HDL
metabolism and structure–function relationships is therefore crucial to exploit
HDLs and its associated components and cellular pathways as potential targets
for anti-atherosclerotic therapies and diagnostic markers.
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1 Introduction
Atherothrombotic diseases, such as coronary heart disease, stroke, and peripheral
arterial disease, are the world’s leading cause of death. The first-line therapy for
prevention and treatment of coronary heart disease is low-density lipoprotein
(LDL) lowering by statin therapy. Although statin drugs are very effective in
reducing plasma LDL cholesterol concentrations, the risk of major cardiovascular
events is only decreased by 15–40 % (Baigent et al. 2005; Ridker et al. 2010).
Additional therapeutic approaches are needed to minimize this considerable
remaining cardiovascular risk in statin-treated patients. It has been postulated that
part of this residual risk may be explained by low circulating levels of high-density
lipoproteins (HDLs). Clinical and large population-based epidemiological studies
have consistently shown that low HDL cholesterol is independently associated with
an increased risk of atherothrombotic diseases (Di Angelantonio et al. 2009; Barter
et al. 2007a). However, this long-standing inverse relationship between HDL and
atherosclerotic cardiovascular disease has been challenged by recent findings.
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Indeed, high plasma concentrations of HDL cholesterol might not be beneficial for
certain subgroups of patients. Thus, in high-risk postinfarction patients
characterized by high total cholesterol and C-reactive protein, elevated levels of
HDL cholesterol were paradoxically found to be related to poor clinical outcome
(Corsetti et al. 2006). Similarly, the inverse relationship between HDL cholesterol
levels and major cardiovascular events was found lost in patients with established
coronary artery disease undergoing diagnostic angiography or coronary artery
bypass grafting (Angeloni et al. 2013; Silbernagel et al. 2013). Moreover, several
large randomized clinical trials assessing the effects of new therapies targeting
HDL metabolism, such as cholesteryl ester transfer protein (CETP) inhibitors and
niacin, reported disappointing results. The Investigation of Lipid Level Manage-
ment to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
revealed that the combination of atorvastatin with the CETP inhibitor torcetrapib
increased HDL cholesterol levels by 72.1 % relative to atorvastatin alone (Barter
et al. 2007b). This raise in HDL cholesterol upon torcetrapib administration did,
however, not lower the risk of the major cardiovascular outcome (Barter
et al. 2007b). On the contrary, patients in the atorvastatin/torcetrapib group unex-
pectedly experienced significantly more adverse events (Barter et al. 2007b). More
recently, another phase 3 clinical trial involving patients with a recent acute
coronary syndrome, named dal-OUTCOMES, was designed to evaluate the effects
of the CETP inhibitor dalcetrapib (Schwartz et al. 2012). Addition of dalcetrapib to
statin therapy raised HDL cholesterol levels by 31–40 % but failed to reduce the
risk of recurrent cardiovascular events (Schwartz et al. 2012). Niacin is another
effective agent for raising HDL cholesterol and also lowering LDL cholesterol,
triglycerides, and lipoprotein(a). Data from the Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health
Outcomes (AIM-HIGH) trial, which included patients with established cardiovas-
cular disease, showed that adding extended-release niacin to statin therapy was not
effective in reducing the risk of cardiovascular events during a follow-up of
36 months despite a 25 % increase in HDL cholesterol (Boden et al. 2011).
Genetic studies also questioned a role for HDLs in atherothrombotic diseases.
Lifelong reductions of plasma HDL cholesterol levels due to heterozygosity for a
loss-of-function mutation in ABCA1 did not affect the risk for ischemic heart
disease (Frikke-Schmidt et al. 2008). Likewise, genetic variation in the apolipopro-
tein A-I (apoA-I) gene, APOA1, affecting apoA-I and HDL cholesterol levels did
not predict ischemic heart disease or myocardial infarction in the general popula-
tion (Haase et al. 2010). A more recent Mendelian randomization analysis
demonstrated that there is no significant association between risk of myocardial
infarction and a loss-of-function SNP in the gene coding for endothelial lipase
(LIPG Asn396Ser), which results in elevated levels of HDL cholesterol (Voight
et al. 2012). Hence, there is ongoing discussion whether HDLs are causally
involved in the development of atherothrombotic diseases or are merely an innocent
bystander. On the other hand, there is considerable evidence from in vitro and
in vivo studies that HDL particles isolated from human plasma as well as artificially
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reconstituted HDLs (rHDLs) exert multiple atheroprotective effects (Annema and
von Eckardstein 2013).
The above-outlined controversies have shifted the interest of the cardiovascular
research field to HDL functionality, meaning that the functional quality of the
particles might be more important than the absolute amount of HDL cholesterol.
Currently, the available HDL-targeted therapies for atherothrombotic diseases raise
plasma HDL cholesterol levels per se. Nonetheless, plasma concentrations of HDL
cholesterol do not necessarily reflect the functional capacity of HDL particles. In
addition, there is evidence that the anti-atherogenic functions of HDLs are impaired
in patients with cardiovascular disease (Annema and von Eckardstein 2013), and
these dysfunctional HDLs might even promote atherothrombotic diseases. There-
fore, a better understanding of the molecular mechanisms behind the protective
functions of HDLs in the context of atherothrombotic diseases is fundamental for
successful exploitation of HDLs for the treatment of coronary heart disease.
2 Interactions of HDLs with the Endothelium
2.1 Preservation of Endothelial Integrity
Perturbations in the function of endothelial cells lining the lumen of blood vessels are
an important hallmark of the earliest stages of the atherosclerotic process. HDLs may
improve or help reverse endothelial dysfunction by several endothelial-vasoprotective
means. Several in vitro studies indicate that HDLs are able to counteract endothelial
cell death. Treatment of endothelial cells with HDLs caused a marked attenuation of
apoptosis in response to pro-atherogenic signals such as oxidized LDL (Suc et al. 1997;
de Souza et al. 2010; Kimura et al. 2001), tumor necrosis factor α (TNFα) (Sugano
et al. 2000; Riwanto et al. 2013), and growth factor deprivation (Kimura et al. 2001;
Nofer et al. 2001b; Riwanto et al. 2013). Although the underlying mechanism has not
been fully elucidated, it has been suggested that HDLs regulate endothelial cell survival
by interfering with critical steps in apoptotic pathways. Several studies reported that
HDLs block the activation of the mitochondrial pathway of apoptosis by preventing
depolarization of the mitochondrial transmembrane and subsequent mitochondrial
release of cytochrome c and apoptosis-inducing factor into the cytoplasm (Nofer
et al. 2001b; de Souza et al. 2010). As a consequence, HDLs inhibit the cytochrome
c-initiated caspase activation cascade (Sugano et al. 2000; Nofer et al. 2001b; de Souza
et al. 2010). Moreover, levels of the apoptosis-inducing protein truncated Bid are
reduced in endothelial cells cultured in the presence of HDLs, whereas endothelial
expression of the antiapoptotic protein Bcl-xL is enhanced (Riwanto et al. 2013). The
capacity of HDLs to attenuate apoptosis in endothelial cells requires induction of
phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS)
signaling (Nofer et al. 2001b; Riwanto et al. 2013) and was attributed to apoA-I
(Radojkovic et al. 2009) as well as HDL-associated lysophospholipids (Kimura
et al. 2001; Nofer et al. 2001b). More recently, a lower clusterin (or apoJ) and increased
apoC-III content in the HDLs of patients with stable coronary artery disease or acute
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coronary syndrome was found to be associated with reduced antiapoptotic activities in
human endothelial cells (Riwanto et al. 2013).
Disruption of vascular endothelium integrity is another central event promoting
atherosclerotic plaque formation. Sphingosine-1-phosphate (S1P), a bioactive
sphingolipid metabolite, has been identified as an important endothelial barrier
function-enhancing agonist (Garcia et al. 2001). In plasma S1P preferentially
associates with HDL particles via binding to apoM (Christoffersen et al. 2011). In
vitro studies provided evidence that delivery of S1P carried by apoM-containing
HDLs to S1P1 receptors on endothelial cells leads to activation of Akt and eNOS,
which in turn promotes endothelial barrier integrity (Argraves et al. 2008;
Wilkerson et al. 2012). Interestingly, the lung vascular barrier function, as deter-
mined by Evan’s blue extravasation, is decreased in mice that lack S1P in their
HDL fraction due to deficiency of apoM (Christoffersen et al. 2011). These data
underline a significant role of HDL-associated S1P in endothelial barrier protection
in vivo. In this context it is important to highlight the submicromolar concentration
of S1P in HDLs which amounts to only 5–10 % of HDL particle concentration but is
in the range of the affinity constants of the G-protein-coupled S1P receptors
(Annema and von Eckardstein 2013; Karuna et al. 2011). Moreover, erythrocytes
release S1P in response to HDLs (Lucke and Levkau 2010) so that in vivo the local
concentration of S1P may be considerably higher than in isolated HDLs.
Acceleration of reendothelialization after vascular injury is another mechanism
proposed to contribute to the positive influence of HDLs on endothelial function. In
this respect, HDLs might be specifically important in driving endothelial cell
migration during repair. Incubation of cultured endothelial cells with HDLs
stimulated cell migration in response to wounding (Seetharam et al. 2006). More-
over, hepatic expression of human apoA-I rescued the impaired carotid artery
reendothelialization following perivascular electric injury in apoA-I knockout
mice (Seetharam et al. 2006). The promotion of endothelial cell migration by
HDLs has been demonstrated to involve scavenger receptor BI (SR-BI)-mediated
activation of Rac-directed formation of actin-based lamellipodia (Seetharam
et al. 2006). An SR-BI-dependent mechanism for the promigratory actions of
HDL was confirmed by experiments showing that the capacity of HDLs to stimulate
endothelial cell migration was reduced by transfection of endothelial cells with
siRNA specific to PDZ domain-containing protein 1 (PDZK1), an SR-BI adaptor
protein that controls steady-state SR-BI levels, and that the reendothelialization
capacity of injured vessels is lost in mice in which the pdzk1 gene has been
disrupted (Zhu et al. 2008). Other studies suggested that HDL-induced endothelial
cell migration is mediated by stimulation of Akt/eNOS phosphorylation through
HDL-bound S1P in an S1P1-dependent manner and that this process is facilitated
by endothelial lipase (Tatematsu et al. 2013).
Besides endothelial cell migration, also recruitment and incorporation of bone
marrow-derived endothelial progenitor cells (EPCs) to sites of vessel injury
contributes to the repair of the damaged vessel wall. HDLs activate the PI3K/Akt
pathway in EPCs resulting in enhanced EPC proliferation, migration, and survival
(Sumi et al. 2007; Petoumenos et al. 2009; Zhang et al. 2010). Moreover,
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preincubation of EPCs with HDL augmented their adhesive capacity to endothelial
cells and potentiated their transendothelial migration (Petoumenos et al. 2009).
Mice that were injected with rHDLs had an increased number of circulating EPCs
and showed improved reendothelialization after carotid artery injury (Petoumenos
et al. 2009). Additional mouse studies indicated that infusion of rHDLs enhanced
bone marrow progenitor cell mobilization, neovascularization, and functional
recovery after hind limb ischemia in wild-type mice (Sumi et al. 2007). In contrast,
no beneficial effects of rHDL treatment on ischemia-induced angiogenesis were
observed in eNOS knockout mice (Sumi et al. 2007), suggesting an essential role
for eNOS in mediating HDL-stimulated EPC recruitment and the subsequent
functional effects on the ischemic limb. There is some evidence that HDLs also
affect circulating EPCs in humans. In patients with coronary artery disease, higher
HDL cholesterol levels were significantly correlated with higher circulating EPC
numbers (Petoumenos et al. 2009). These findings are corroborated by data from a
study in patients with type 2 diabetes mellitus which found that rHDL infusion at a
dose of 80 mg/kg body weight markedly increased circulating EPC levels compared
to baseline (van Oostrom et al. 2007).
2.2 Preservation of Endothelial Function
Other reports on HDL functionality in endothelial cells established that HDLs have
direct effects on vascular endothelium-relaxing properties. HDLs induce
endothelium-derived vasorelaxation in aortic segments ex vivo in a dose-dependent
manner (Nofer et al. 2004). Mechanistically, binding of HDL to SR-BI and the
lysophospholipid receptor S1P3 on endothelial cells leads to PI3K-stimulated
activation of Akt and mitogen-activated protein (MAP) kinase pathways, and Akt
in turn phosphorylates eNOS at Ser-1177 to increase endothelial nitric oxide
(NO) production and ultimately endothelium-dependent vasorelaxation (Nofer
et al. 2004; Mineo et al. 2003; Yuhanna et al. 2001). The stimulatory effect of
HDLs on NO-dependent vasorelaxation could be mimicked by three
HDL-associated lysophospholipids, i.e., sphingosylphosphorylcholine, S1P, and
lysosulfatide (Nofer et al. 2004). In addition to eNOS activation, modulation of Akt
and MAP signaling by HDLs has been reported to delay the degradation of eNOS
mRNA in endothelial cells, thereby upregulating eNOS protein levels (Ramet
et al. 2003). Dietary oxysterols, in particular 7-oxysterols, impair endothelial
vasorelaxant function by disrupting the active dimeric form of eNOS and by inducing
production of reactive oxygen species (ROS) (Terasaka et al. 2010). HDLs can
counteract the negative effects of 7-oxysterols on endothelial eNOS function by
promoting efflux of 7-oxysterols from endothelial cells via ATP-binding cassette
transporter G1 (ABCG1) (Terasaka et al. 2010). The same researchers revealed that
HDL-mediated removal of cholesterol and oxysterols from endothelial cells through
ABCG1 could reverse the cholesterol loading-induced inactivation of eNOS resulting
from its increased interaction with caveolin (Terasaka et al. 2010). Similar to NO,
there is evidence to suggest that the release of the endothelium-derived vasodilator
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prostacyclin can be influenced by HDLs. In human umbilical vein endothelial cells,
HDLs elevated cyclooxygenase-2 protein expression and thereby induced prostacy-
clin synthesis via a pathway that involved PKC, ERK1/2, and sphingosine kinase
SphK-2 (Xiong et al. 2014). The human relevance of these findings is underscored by
studies demonstrating that infusion of rHDLs in hypercholesterolemic patients led to
normalization of endothelium-dependent vasodilation in response to acetylcholine
(Spieker et al. 2002). Moreover, heterozygosity for a loss-of-function mutation in
ABCA1 has been reported to be associated with low levels of HDL cholesterol as well
as an impaired endothelium-dependent forearm vasodilatory response, a phenotype
which could be restored by intravenous administration of apoA-I/
phosphatidylcholine discs (Bisoendial et al. 2003).
3 Anti-inflammatory Effects
3.1 Suppression of Myelopoiesis
Vascular inflammation, one of the main forces driving the formation of atheroscle-
rotic plaques, is accompanied by the rolling, firm adhesion, and subsequent migra-
tion of monocytes across the vascular endothelium. A first critical determinant for
monocyte transmigration is the number of monocytes present in the circulation.
HDL-mediated cholesterol efflux pathways appear to play a prime role in the
proliferation of myeloid cells in the bone marrow, cell mobilization from the
bone marrow, and subsequent myeloid differentiation, at least in mice. Mice that
lack both ABCA1 and ABCG1 have increased numbers of myeloid progenitor
cells in bone marrow, blood, spleen, and liver, suggestive of aberrant myeloproli-
feration, myeloid progenitor cell mobilization, and extramedullary hematopoiesis
(Yvan-Charvet et al. 2010; Westerterp et al. 2012). As a consequence monocyte
counts in blood are elevated in ABCA1 x ABCG1 double knockout mice (Yvan-
Charvet et al. 2010). In addition, the myeloproliferative phenotype and the
enhanced mobilization of hematopoietic progenitor cells associated with bone
marrow deficiency of ABCA1 and ABCG1 were reversed in mice carrying a
human apoA-I transgene, and in high cholesterol diet-fed LDL receptor knockout
mice, this was associated with less severe atherosclerosis (Yvan-Charvet
et al. 2010; Westerterp et al. 2012). Correspondingly, raising HDL cholesterol
levels in other murine models of myeloproliferative disorders also efficiently
reduced the appearance of hematopoietic progenitor cells in the circulation
(Westerterp et al. 2012). Direct proof for a link between HDL and myeloproli-
feration was provided by experiments showing that incubation of myeloid progeni-
tor cells with HDLs ex vivo suppressed cell expansion (Yvan-Charvet et al. 2010).
Taken together, these findings indicate that HDLs may beneficially impact the
number of circulating monocytes. In humans there is some evidence for a correla-
tion between HDL cholesterol levels and monocyte numbers in patients with
familial hypercholesterolemia (Tolani et al. 2013). However, only few and incon-
sistent data on the association between monocyte counts and risk of atherosclerotic
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vascular disease in humans has been reported. In addition, it will be important to
consider the heterogeneity of monocytes for any association with coronary heart
disease (Zawada et al. 2012).
3.2 Suppression of Monocyte Extravasation
The arrest of circulating monocytes on inflamed endothelial monolayers is triggered
by chemokines and their corresponding receptors, which both have been
demonstrated to be subject to regulation by HDLs. Infusions of lipid-free apoA-I
in apoE-deficient mice that were fed a high-fat diet reduced the relative abundance
of cells stained positive for the chemokine receptors CCR2 and CX3CR1 in
atherosclerotic plaques in the aortic sinus and decreased the circulating levels of
the chemokines CCL2 and CCL5 (Bursill et al. 2010). Moreover, in vitro rHDLs
were found to downregulate cell surface expression of chemokine receptors on
monocytes and to render human monocytes and endothelial cells partly resistant to
phytohemagglutinin- or cytokine-induced expression of chemokines (Bursill
et al. 2010; Spirig et al. 2013). Although it was shown that HDLs counterbalance
the upregulation of chemokines in response to pro-inflammatory cytokines by
reducing nuclear factor-κβ (NF-κβ) pathway activation, how HDLs modulate
monocyte expression of chemokine receptors on the molecular level remains to
be established (Bursill et al. 2010). In addition to these effects on monocytes and
endothelial cells, HDLs were also able to limit the production of CCL2 in vascular
smooth muscle cells (VSMCs) exposed to thrombin (Tolle et al. 2008). The study
identified HDL as a negative regulator of thrombin-induced activation of Rac1-
dependent NADPH oxidases and subsequent ROS generation. This process is
mediated by binding of HDL to SR-BI on VSMCs, and moreover lysosphingolipids
present in HDL particles can act on local S1P3 receptor to inhibit CCL2 expression
(Tolle et al. 2008).
Once monocytes are attracted by chemokines to inflamed endothelium,
monocyte–endothelial cell interactions are mediated by several cell adhesion
molecules. Experiments in vitro provided compelling evidence that cytokine-
induced adhesion molecule expression on the endothelial cell surface is diminished
in the presence of either native HDLs (Cockerill et al. 1995; Ashby et al. 1998) or
rHDLs (Baker et al. 1999; Clay et al. 2001). Notably, the effects of HDLs on
endothelial expression of adhesion molecules not only occurred in cultured cells but
also in the in vivo setting under inflammatory conditions. For example, a single
injection of discoidal rHDL particles in pigs prevented upregulation of E-selectin
expression in response to intradermal interleukin-1α (Cockerill et al. 2001). More-
over, daily treatment of normocholesterolemic rabbits with rHDLs or lipid-free
apoA-I markedly attenuated periarterial collar-induced endothelial expression of
vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule
1 as well as concomitant neutrophil infiltration into the vessel wall and generation
of ROS (Nicholls et al. 2005). The positive effects of lipid-free apoA-I on
pro-inflammatory vascular changes were still observed when administered as a
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single low dose 3 h after insertion of the non-occlusive periarterial collar (Puranik
et al. 2008), indicating that infusion of apoA-I may also be able to rescue
preestablished vascular inflammation. In patients suffering from claudication, treat-
ment with rHDLs led to a significant reduction in the percentage of VCAM-1
positive cells in femoral artery lesions (Shaw et al. 2008). Diminution of adhesion
molecule expression on endothelial cells by HDLs may involve the activation of
multiple receptors and signaling cascades. There are data supporting that HDLs
alter adhesion molecule expression as a consequence of perturbation of cellular
sphingolipid metabolism and the NF-κβ signaling pathway. HDL3 was found to
impede TNFα-induced upregulation of VCAM-1 and E-selectin expression in
human umbilical vein endothelial cells by antagonizing activation of sphingosine
kinase and subsequent intracellular formation of S1P (Xia et al. 1999). Further-
more, it has been documented that in cultured endothelial cells, incubation with
HDLs prevented NF-κβ activation, movement of p65 to the nucleus, and expression
of NF-κβ target genes in response to TNFα (Xia et al. 1999; Park et al. 2003;
Kimura et al. 2006; McGrath et al. 2009). The basal molecular mechanisms of
the beneficial effects of HDL on endothelial inflammation are dependent on an
increase in the expression of 3β-hydroxysteroid-Δ24 reductase that results in
activation of PI3K and downstream activation of eNOS and heme oxygenase-1
(HO-1) (McGrath et al. 2009; Wu et al. 2013). Specific knockdown of SR-BI or
S1P1 receptor by treatment of human endothelial cells with small interfering RNAs
against SR-BI and PDZK1 or S1P1, respectively, markedly reduced the ability of
HDLs to inhibit VCAM-1 expression and NF-κβ activation (Kimura et al. 2006; Wu
et al. 2013), suggesting that both receptors may be critical for the anti-inflammatory
endothelial actions of HDLs. Corresponding with the possible involvement of the
S1P1 receptor, the inhibitory activity of HDLs on the expression of endothelial cell
adhesion molecules has been proposed to be a function of biologically active
lysosphingolipids carried by HDL particles (Nofer et al. 2003; Kimura
et al. 2006). Besides the lipid component, the anti-inflammatory properties of
HDLs could also be related to the microRNA content of HDL particles. Recently,
it has been reported that transfer of microRNA-223 by HDLs to human aortic
endothelial cells significantly repressed expression of intracellular adhesion mole-
cule 1 (Tabet et al. 2014).
Monocytes bind to adhesion molecules on activated endothelial cells through
monocytic cell surface receptors, such as CD11b. Ex vivo incubation of stimulated
human peripheral blood monocytes with apoA-I in the lipid-free or HDL-associated
state caused a reduction in cell surface expression of CD11b (Murphy et al. 2008).
These results might be directly translatable to the human in vivo situation, as
evidenced by the observation that infusion of rHDLs in patients with atherosclerosis
disease in the femoral artery led to a significantly lower expression of CD11b on
circulating monocytes (Shaw et al. 2008). The fact that cellular depletion of
cholesterol by cyclodextrin mimicked the protective effects of apoA-I on the
expression of monocyte CD11b and that inhibition of CD11b expression is lost in
the presence of an antibody against ABCA1 or in monocytes derived from Tangier
disease patients is indicative of a role for ABCA1-mediated cholesterol efflux in the
mechanism of monocyte deactivation by apoA-I (Murphy et al. 2008).
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3.3 Interference with Macrophage Differentiation and Activation
Monocytes that have entered the arterial intima subsequently differentiate into
resident macrophages of at least two major subtypes that differentially produce a
variety of pro- and anti-inflammatory mediators. In the subendothelial space, the
macrophages become activated and comprise key targets for the anti-inflammatory
action of HDLs. Incubation with HDLs primed isolated murine bone marrow
macrophages into alternative M2 macrophages with anti-inflammatory features
(Sanson et al. 2013). Moreover, HDLs were potent inhibitors of interferon-
gamma-mediated expression of pro-inflammatory M1 markers in isolated mouse
macrophages, and, interestingly, experiments performed with macrophages from
STAT6-deficient mice demonstrated that STAT6 plays an essential role in the
HDL-mediated shift of the macrophage phenotype to M2 (Sanson et al. 2013).
However, other investigators could not replicate these observations, when using
primary human monocyte-derived macrophages (Colin et al. 2014). A recent study
provided novel mechanistic insights into the anti-inflammatory effects of HDLs in
macrophages. Thus, administration of native HDL, rHDL, or apoA-I to mice
challenged with a toll-like receptor (TLR) agonist protected from liver damage
and reduced serum levels of pro-inflammatory cytokines, which was supposed to be
due the ability of HDLs to reduce cytokine production in activated macrophages
(De Nardo et al. 2014). The anti-inflammatory action of HDL particles on
macrophages was explained by their ability to induce the expression of activating
transcription factor 3 (ATF3), which functions as a repressor of pro-inflammatory
target genes (De Nardo et al. 2014).
During the past decades, a considerable amount of data has been published
revealing that natural regulatory T cells, which dampen inflammatory responses,
may help decrease the atherosclerotic disease burden. The findings of a recent
murine study imply that apoA-I could promote the expansion of regulatory T cells.
Subcutaneous injection of human lipid-free apoA-I in LDL receptor/apoA-I double
knockout mice fed an atherogenic diet restored the regulatory T-cell population in
the lymph nodes (Wilhelm et al. 2010). In these animals the raise in the number of
regulatory T cells in the lymph nodes was accompanied by a reversal of the
inflammatory and autoimmune phenotype.
4 Effects of HDLs on Vascular Lipid and Lipoprotein
Homeostasis
4.1 From LDL Retention to Atheroma Formation
4.1.1 Initial Lipid Accumulation in Atherosclerosis-Prone Arterial
Intima: A Sign of LDL Retention
The intima is disproportionally thick at the outer curvatures of the proximal
branches of coronary and carotid arteries, where turbulent flow conditions prevail
and the pulse wave amplitude is relatively high (Wentzel et al. 2012). The
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thickening is a physiological response to these conditions and ensues when the
vascular smooth muscle cells (VSMCs) divide and secrete various components of
the extracellular matrix at the stressed sites. One major factor explaining the
relationship between the thickness of the intima and its susceptibility to atheroscle-
rotic lesion development is the lack of a capillary delivery system and lack of a
lymphatic drainage system in this tissue (Hulten and Levin 2009; Eliska
et al. 2006). As a consequence, the inflowing apoB100-containing lipoprotein
particles (notably LDL and also VLDL remnants) are only slowly conveyed by
the intimal fluid from the subendothelial superficial layer into the deeper intimal
layers and ultimately to the medial layer of the arterial wall where lymphatic
capillaries are present. Indeed, in cholesterol-fed rabbits, intimal LDL concentra-
tion initially increases in atherosclerosis-susceptible sites, where their intimal
residence time of the LDL particles is long, the transit time being calculated to be
hours (Schwenke and Carew 1989a, b).
Since progressive accumulation of LDL cholesterol is a key feature of athero-
genesis, we can deduce that some intimal LDL particles never leave the site. The
constant inflow without compensatory outflow of LDL particles results in a dra-
matic increase in their concentration in the intimal fluid to reach values equaling or
even exceeding (by twofold) those in the corresponding human blood plasma
(Smith 1990). Thus, the concentration of LDL in the arterial intimal fluid is
10–20 times higher than in the extracellular fluids of other extrahepatic tissues, in
which its concentration is about 1/10th of that in the corresponding plasma, so
rendering the intima a truly “hypercholesterolemic” site.
During their lengthy passage across the thick avascular tissue, the LDL particles
tend to bind to the subendothelial extracellular proteoglycan matrix, a phenomenon
known as retention of LDL (Williams and Tabas 1995). The proteoglycans form a
tight network that is negatively charged. To this network the LDL particles bind via
ionic interactions, when positively charged lysine and arginine residues located in
the proteoglycan binding site of apoB100 interact with the negatively charged
sulfate groups of the glycosaminoglycan components of the proteoglycans (Camejo
et al. 1998). The prolonged residence time of LDL particles in the intima, whether
the particles are in solution or trapped in the matrix, enhances their exposure to a
variety of local LDL-modifying factors. Thus, during their long extracellular
residence time, the LDL particles are modified, for example, by oxygen radicals
secreted by the resident cells of the intima, notably by endothelial cells, and also by
SMCs. It is of particular relevance that the endothelial cells become activated to
secrete pro-oxidative compounds at sites with turbulent flow, i.e., at the
atherogenesis-prone sites of the arterial tree (Nigro et al. 2011). Moreover, the
subendothelially located LDL particles are not protected by the powerful antioxi-
dant systems present in the circulating blood plasma, and they also gradually
become depleted of their own antioxidant molecules capable of protecting them
from free radical attack and oxidation (Esterbauer et al. 1991). In addition to the
oxidative processes, various hydrolytic (both proteolytic and lipolytic) enzymes
may also modify the LDL particles in the intima (Tabas 1999). Importantly, the
oxidative and hydrolytic changes of LDL particles render them unstable, trigger
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their aggregation and fusion into lipid droplets, and markedly strengthen their
binding to arterial proteoglycans (Oorni et al. 2000). These in vitro observations
have their close counterparts in various animal models, and also in the human
carotid arteries, in which tiny proteoglycan-, collagen-, and elastin-associated lipid
deposits, detectable only by aid of special electron microscopic techniques, are
located in the subendothelial extracellular space even before any microscopic signs
of atherosclerosis are visible (Nievelstein-Post et al. 1994; Tamminen et al. 1999;
Pasquinelli et al. 1989).
4.1.2 Formation of a Fatty Streak
As stated above, atherosclerosis typically develops at certain predilection sites as a
response to the hemodynamic stress and other types of injury affecting the endo-
thelial cells. Importantly, in such stressed areas with disturbed flow conditions,
endothelial inflammatory signaling pathways become activated and a local
pro-inflammatory environment is created (Nigro et al. 2011). We can consider
this local scenario as a singular starting condition to the development of atheroscle-
rosis. Thus, the flow-mediated preconditioning of the intima renders it a suitable
soil for the retention, modification, and accumulation of LDL particles. Because the
subendothelially located modified LDL particles and the products released from
them are pro-inflammatory, they are likely to have profound local cell-activating
effects and to worsen the inflammation by inducing local generation of various
LDL-modifying enzymes and agents and so creating a positive feedback loop
(Pentikainen et al. 2000; Tabas et al. 2007). Moreover, synthesis and secretion of
pro-inflammatory cytokines and chemokines, such as the monocyte chemotactic
protein-1 (MCP-1; CCL2), are induced (Libby 2002; Zernecke and Weber 2010).
Indeed, monocytes preferentially adhere to the endothelium covering inflamed
tissue sites, i.e., regarding atherogenesis, they tend to enter the intimal areas
containing oxidized or otherwise modified LDL particles (Schmitt et al. 2014a, b).
The extracellularly located modified LDL particles, whether free floating in the
intimal fluid or whether matrix bound, are ingested by intimal macrophages and, to
some extent, also by intimal SMCs (Witztum 2005; Wang et al. 1996). On their
surfaces, the macrophages express scavenger receptors, which recognize oxidized
and otherwise modified LDL particles (Krieger and Herz 1994). The macrophages
may also phagocytose modified LDL particles, provided the particles are in aggre-
gate form or have been converted into droplets via fusion. Since uptake of LDL
cholesterol by macrophages is not negatively feedback regulated by the inflowing
cholesterol, uptake of LDL cholesterol, be it scavenger receptor dependent or
mediated by other mechanisms, may continue until the cells are filled with choles-
terol (Brown and Goldstein 1983). Of great interest, also unmodified native LDLs
can be ingested by macrophages at a rate which is linear to their concentration in the
extracellular fluid (Kruth 2011). Since the concentration of LDL in the intimal fluid
is exceptionally high (see above), such micropinocytotic uptake of LDLs by
macrophages may actually be of great significance in the atherosclerosis-prone
arterial intima.
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In the macrophages, the excess of intracellular cholesterol is esterified with fatty
acids and stored in their cytoplasm as cholesteryl ester droplets (Brown and
Goldstein 1983). Macrophages full of such droplets look foamy under the micro-
scope and are called foam cells. When numerous foam cells form clusters, they
have yellow appearance visible to the naked eye and the site appears as a fatty
streak (Stary et al. 1994). Importantly, when fatty streaks develop in human carotid
arteries, the subendothelial perifibrous lipid droplets disappear (Pasquinelli
et al. 1989). This switch conceivably reflects uptake of the perifibrous droplets by
the subendothelial macrophages. Thus, in a fatty streak the LDL-derived choles-
terol is located mostly intracellularly. Taken together, an important role of
subendothelial macrophages in the arterial intima is to clear unmodified or modified
LDL particles from their surrounding and to store their cholesterol as cholesteryl
esters. Indeed, foam cells in the arterial intima are the most defining feature of
atherosclerosis.
HDLs directly bind unesterified cholesterol. As the consequence, HDL can
mobilize unesterified cholesterol both from cells and extracellular locations (Free-
man et al. 2014). Regarding cholesteryl esters, the extracellularly stored esters,
present either in the core of the matrix-bound LDL particles or in the core of the
perifibrous lipid droplets derived from modified LDL particles, are likely to fully
resist transfer to HDLs. In sharp contrast, intracellular cholesterol stored as
cholesteryl esters in the cytoplasmic lipid droplets of macrophage foam cells is
sensitive to transfer to HDLs (Rosenson et al. 2012). Thus, regarding the return of
LDL cholesterol from the arterial intima back to the circulating blood, it appears to
be of fundamental importance that the LDL particles are first taken up and
metabolized by intimal macrophages. Accordingly, this macrophage-dependent
preparative step appears to be mandatory for the initiation of reverse cholesterol
transport in the arterial intima. However, since the macrophages accumulate
LDL-derived cholesterol, an imbalance between cholesterol influx and cholesterol
efflux exists in the atherosclerosis-prone arterial intima. One reason for the relative
inability of HDLs to effectively remove cholesterol from the intimal macrophages
is their functional modification including proteolysis, oxidation, and lipolysis to
various extents (Lee-Rueckert and Kovanen 2011; DiDonato et al. 2013).
4.1.3 Development of an Atheroma
Conversion of a fatty streak into an atheroma is the next phase in atherogenesis
(Stary et al. 1995). It is characterized by extracellular accumulation of cholesterol
in the deep layers of the intima, i.e., below the superficial foam cell layers.
However, in sharp contrast to the superficial layers of the intima, where atherogen-
esis initiates and where macrophages swiftly arrive and efficiently remove the lipids
so preventing their extracellular accumulation, in the deep layers, the macrophages
arrive late (Nakashima et al. 2008). Accordingly, once formed, the deep extracellu-
lar lipids are not rapidly scavenged by macrophages. Rather, the continuous
formation of lipid droplets without their concomitant removal leads to their pro-
gressive deposition, which ultimately leads to the appearance of “lipid lakes”. The
lakes consist of huge numbers of such droplets, and together the lakes form a lipid
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core (Guyton and Klemp 1996). The presence of a lipid core is the hallmark of an
atheroma.
During the process of lipid core formation, macrophages start to migrate from
the superficial layer into the deep intimal area where they ingest the extracellular
lipid droplets in the periphery of the lipid core and themselves become converted
into foam cells. Since the deep intimal region is distant from the circulating blood, it
easily becomes hypoxic (Hulten and Levin 2009). Although survival mechanisms
are activated in macrophages trapped in such hypoxic areas (Ramkhelawon
et al. 2013), promotion of lipid accumulation, ATP depletion, and immobilization
of the macrophage foam cells is likely to ultimately lead to their death. Of note,
death of a foam cell is bound to liberation of its cytoplasmic cholesteryl ester
droplets into the extracellular space, where the droplets mix with the preexisting
extracellular lipid droplets. Moreover, the nonviable macrophages (foam cells) fail
to effectively remove the cellular debris derived from the dying or dead foam cells
(Thorp et al. 2011), so leaving the formed debris deposited among the lipids of the
growing core. A lipid core also containing remnants derived from dead cells is
called a “necrotic lipid core”.
In summary, regarding cholesterol metabolism in the arterial intima, the super-
ficial and the deep layers appear to be fundamentally different. Mechanistically, in
the superficial compartment of the arterial intima, viable macrophages ingest and
store LDL cholesterol as cholesteryl esters, and transfer it to HDLs for ultimate
return to the circulation, continual hydrolysis of the cytoplasmic cholesteryl esters
being the critical factor for the transfer of cholesterol from LDL to HDL. In
contrast, in the deep intimal compartment, macrophages only inefficiently remove
LDL cholesterol, and, provided a macrophage is converted into a foam cell, it may
die and release its cholesteryl ester cargo into the extracellular space, where the
cholesteryl esters are not available for removal by HDLs. Thus, in the absence of an
efficient transfer of cholesterol from LDL to HDL, the necrotic lipid core grows
progressively and may convert an atheroma into a clinically significant atheroscle-
rotic lesion.
4.2 Inhibition of LDL Modification by HDLs
Resident macrophages in the subendothelial space take up oxidized LDLs via
scavenger receptors and become macrophage foam cells, the hallmark cell type of
atherosclerotic lesions. HDLs have been proven to help to reduce the formation of
lipid-laden macrophage foam cells by rendering LDL particles resistant to oxida-
tion. Preexposure of LDL particles to apoA-I or mature HDL particles completely
prevented the oxidative modification of LDLs by cultured human aortic endothelial
cells and SMCs (Navab et al. 2000). Moreover, the human artery wall cells were no
longer able to oxidize LDLs isolated from mice and humans that received a single
treatment with human apoA-I. Likewise, HDLs have been shown to possess potent
antioxidative activity in chemical in vitro models for oxidative modifications of
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LDLs, using, for example, copper ions (Parthasarathy et al. 1990) or the more mild
oxidizing agent 2,20-azobis(2-amidinopropane) dihydrochloride (AAPH) (Kontush
et al. 2003). At least part of the ability of HDLs to inhibit LDL oxidation was
attributed to the capacity of apoA-I to remove seeding molecules present in freshly
isolated LDLs (Navab et al. 2000). Notably, the reduction of lipid hydroperoxides
to their corresponding hydroxides by HDLs was associated with the selective
oxidation of Met residues in apoA-I to their Met sulfoxide form (Garner
et al. 1998), suggesting that Met residues in apoA-I may act as endogenous
antioxidants within the HDL particle.
In addition to apoA-I, antioxidant properties of HDLs are conferred by
paraoxonase 1 (PON1), an antioxidant enzyme transported in the circulation by
HDL particles. The inhibitory effect of HDLs on LDL oxidation by human artery
wall cells or copper could be mimicked by incubation of LDLs with purified PON1
(Navab et al. 2000; Liu et al. 2008). After treatment of oxidized phospholipids with
PON1, oxygenated polyunsaturated fatty acids were no longer detectable (Watson
et al. 1995a), indicating that PON1 was able to destroy these multi-oxygenated
biologically active molecules which are abundantly formed during the atherogenic
oxidation of LDL particles. Studies in transgenic and knockout mice on the role of
PON1 in the pathogenesis of atherosclerosis have supported the protective effects
of PON1 on LDL oxidation. The lack of PON1 in the HDL fraction of PON1
knockout mice resulted in an inability of these HDL particles to prevent the
formation of oxidized LDLs, and accordingly pon1-null mice were more suscepti-
ble to atherosclerosis than their wild-type littermates (Shih et al. 1998). Expression
of human PON1 in transgenic mice led to the opposite phenotype. On the
atherosclerosis-prone apoE/ background, mice transgenic for human PON1
developed significantly less atherosclerotic plaques in the aorta than the control
mice. Moreover, in vitro PON1-enriched HDLs from PON1 transgenic/apoE
knockout were more potent inhibitors of copper-catalyzed oxidation of LDL
particles (Tward et al. 2002).
Another antioxidant enzyme that has been related to the cardioprotective
antioxidative function of HDL particles is lipoprotein-associated phospholipase
A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase
(PAF-AH). In human plasma a small proportion of the circulating Lp-PLA2 enzyme
activity is found in HDL particles (Tellis and Tselepis 2009). Inhibition of the
enzymatic activity of Lp-PLA2 rendered HDLs unable to prevent monocyte binding
induced by oxidized LDLs in endothelial cells, and supplementation of the dys-
functional HDL particles with purified Lp-PLA2 restored the normal protective
function (Watson et al. 1995b). In mice, adenovirus-mediated expression of human
Lp-PLA2 leads to a reduction in the autoantibody titers against oxidized LDLs
and malondialdehyde (MDA)-modified LDLs (Quarck et al. 2001; Noto
et al. 2003). Despite the fact that the antioxidative potential of HDL-bound
Lp-PLA2 has been well documented, several lines of evidence suggest that the
presence of Lp-PLA2 in LDL particles may actually stimulate atherogenesis. The
pro-atherogenic actions of Lp-PLA2 in LDLs are thought to arise from oxidized free
fatty acids and lysophospholipids, two inflammatory mediators which are released
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after the hydrolysis of oxidized phospholipids by Lp-PLA2 (Tellis and Tselepis
2009). LDLs are the preferred lipoprotein carriers for Lp-PLA2 in the circulation,
which would explain why previous prospective cohort studies paradoxically linked
high plasma Lp-PLA2 levels with adverse cardiovascular outcomes (Brilakis
et al. 2005; Koenig et al. 2004; Sabatine et al. 2007). In support of the hypothesis
that Lp-PLA2 is atheroprotective only when incorporated in HDL particles, Rallidis
et al. found that elevated total plasma Lp-PLA2 mass and activity increased the risk
for future cardiac death in patients with stable coronary artery disease, while
Lp-PLA2 mass and activity in apoB-depleted plasma showed a significant associa-
tion with future cardiac death in the opposite direction (Rallidis et al. 2012).
The protective effect of HDLs on LDL oxidation has been tentatively ascribed to
the antioxidant activities of lecithin-cholesterol acyltransferase (LCAT). Similar to
HDLs, purified LCAT has been shown to diminish the formation of both lipid
hydroperoxides and conjugated dienes in copper-oxidized LDLs (Vohl et al. 1999).
Moreover, adenovirus-mediated transfer of the human LCAT gene into mice with
combined leptin and LDL receptor deficiency decreased circulating levels of
autoantibodies binding to MDA-LDL by 40 % and accordingly limited the accu-
mulation of oxidized LDLs in the arterial wall (Mertens et al. 2003).
4.3 Macrophage Cholesterol Efflux and Reverse Cholesterol
Transport
The uptake of modified LDLs in arterial macrophages leads to the cellular accumu-
lation of cholesterol and oxidized lipids. This process causes the macrophages to
transform into lipid-laden macrophage foam cells which can no longer escape the
arterial wall (Potteaux et al. 2011). The excessive cellular cholesterol in macro-
phage foam cells can be efficiently removed by the potent cholesterol acceptors
lipid-free apoA-I and HDLs to be transported back to the liver by a process termed
reverse cholesterol transport.
4.3.1 Transendothelial HDL Transport
In order to reach these resident macrophage foam cells in the innermost layer of the
arterial wall, apoA-I and HDLs first need to passage across the endothelial cell
layer. There is cell culture evidence that lipid-free apoA-I binds to specific saturable
high-affinity binding sites on aortic endothelial cells, which is followed by inter-
nalization, transcytosis, and delivery of lipidated apoA-I to the basolateral side
(Rohrer et al. 2006). A similar phenomenon was observed when cultivated aortic
endothelial cells were treated with mature HDLs (Rohrer et al. 2009). However, the
mechanisms involved in regulating this endothelial transport of apoA-I and HDLs
are not fully understood. The ABCA1 transporter is thought to play major role in
the apical-to-basolateral transport of apoA-I in aortic endothelial cells (Cavelier
et al. 2006). Induction of ABCA1 expression by a combination of oxysterol and
9-cis-retinoic acid increased the binding and internalization of apoA-I in endothe-
lial cells, whereas knockdown of endothelial ABCA1 by RNA interference reduced
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the cellular uptake and transcytosis of apoA-I (Cavelier et al. 2006). Conversely,
siRNA-mediated gene silencing experiments revealed that the cell surface binding
and transport of HDLs through aortic endothelial cells are highly dependent on
SR-BI and ABCG1, but not on ABCA1 (Rohrer et al. 2009). Subsequent research
has demonstrated expression of the ectopic β-chain of F0F1 ATPase (β-ATPase) on
the endothelial cell surface (Cavelier et al. 2012). The results of this study further
suggest that the binding of lipid-free apoA-I to endothelial cell surface β-ATPase
facilitates the uptake and transport of lipidated apoA-I and mature HDLs by
enhancing β-ATPase-mediated hydrolysis of extracellular ATP into ADP and
inducing consecutive activation of the purinergic P2Y12 receptor (Cavelier
et al. 2012). More recently, transendothelial transport of HDL particles was found
to be modulated by endothelial lipase both through its enzymatic lipolytic activity
and its ability to bridge the binding of lipoproteins to the endothelial surface
(Robert et al. 2013). Initiation of an atherosclerosis-related inflammatory pheno-
type after stimulation of vascular endothelial cells with interleukin-6 significantly
increased the binding, cell association, and transport of HDLs, which was linked
mechanistically to the increase in endothelial lipase expression in response to
interleukin-6 (Robert et al. 2013).
4.3.2 Cholesterol Efflux from Macrophages
Once apoA-I and HDLs have reached macrophage foam cells in the atheromatous
vessel wall, macrophage cholesterol efflux can be elicited via several different
pathways. It is well documented that lipid-free apoA-I and pre-beta HDL particles
are able to remove cholesterol and phospholipids from macrophage foam cells via
the ABCA1 transporter (Wang et al. 2000; Wang and Tall 2003). It has been
postulated that apoA-I-dependent cholesterol efflux from cells is mediated either
by a direct protein–protein interaction between apoA-I and ABCA1 or indirectly by
ABCA1-induced changes in the membrane cholesterol distribution (Wang and Tall
2003). The ability of ABCA1 to mobilize cellular lipids to apoA-I is essential for
the initial lipidation of apoA-I. The ABCG1 transporter is responsible for a major
part of the macrophage cholesterol efflux towards mature HDL particles (Wang
et al. 2004). Since cellular removal of cholesterol via ABCG1 was not accompanied
by specific binding of HDLs to the plasma membrane (Wang et al. 2004), the
molecular basis of efflux of cholesterol mediated by ABCG1, like ABCA1, is not
fully understood and warrants further investigation. Another cell surface receptor
involved in macrophage cholesterol efflux elicited by mature HDLs is SR-BI.
Binding of HDL to macrophage SR-BI facilitates a bidirectional exchange of
unesterified cholesterol and other lipids between the cell membrane and HDL
acceptor particles according to the cholesterol concentration gradient (de La
Llera-Moya et al. 2001). This cholesterol concentration gradient between cells
and HDL not only allows cholesterol transfer via SR-BI but also passive diffusion
of cholesterol molecules to nearby HDL particles by receptor-independent pro-
cesses (von Eckardstein et al. 2001; Yancey et al. 2003). The HDL-associated
enzyme LCAT catalyzes the esterification of cholesterol in HDL particles
(Calabresi and Franceschini 2010). The generated cholesteryl esters leave the
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particle surface and form the core of the maturing HDL particle; hence, a local
gradient of unesterified cholesterol is created that maintains a continuous flow of
unesterified cholesterol from macrophages towards HDLs (Calabresi and
Franceschini 2010).
4.3.3 Exit from the Arterial Wall
There is little reported data on the route used by HDLs to leave the arterial intima.
Recent lines of evidence support a role for the lymphatic vasculature in the
transport of HDLs from the interstitial space back to the bloodstream. Following
injection of fluorescently labeled HDLs in the mouse footpad, HDLs were subse-
quently found in the draining lymph node and its afferent and efferent lymphatic
vessels (Lim et al. 2013). Moreover, the movement of cholesterol from
macrophages in the footpad to the lymph and plasma was substantially reduced in
mice with surgical interruption of the afferent lymphatic vessels or in Chy mutant
mice that lack dermal lymphatic capillaries (Lim et al. 2013; Martel et al. 2013).
The importance of the lymphatic system in the reentry of cholesterol originating
from macrophages via HDLs in the circulation was further confirmed by additional
experiments showing that the appearance of macrophage-derived cholesterol in the
plasma was impaired after implantation of [3H]-cholesterol-labeled macrophages in
the tail skin of apoA-I transgenic mice with microsurgical ablation of the major
lymphatic conduits in the tail (Martel et al. 2013). To provide more direct proof for
the involvement of the lymphatic vasculature in the transport of cholesterol from
the atherosclerotic plaque, aortic segments with advanced atherosclerotic lesions
were loaded with D6-cholesterol and transplanted in apoE knockout mice (Martel
et al. 2013). Inhibition of regrowth of a functional lymphatic vasculature in the
aortic donor wall by an antibody blocking the function of vascular endothelial
growth factor receptor 3 markedly suppressed the apoE-induced removal of
D6-cholesterol from the transplanted aorta (Martel et al. 2013), hence emphasizing
the pivotal role of the lymphatic system for the egress of cholesterol from the aortic
wall. The entry of HDL particles into lymphatic vessels appears to be primarily
dependent on SR-BI. Experiments in cultured cells demonstrate that the internali-
zation and transcytosis of HDL particles by lymphatic endothelial cells are dimin-
ished by an SR-BI blocking antibody or a selective SR-BI inhibitor (Lim
et al. 2013). In agreement, lymphatic transport of HDLs is compromised in SR-
BI-null mice and in mice treated with an antibody against SR-BI (Lim et al. 2013).
Although not formally tested, it is also possible that, in order to reach the circulation
again, HDL particles undergo transcytosis through the luminal endothelial cell
barrier or transfer cholesterol to endothelial cells for delivery to circulating
HDLs. The importance of a well-regulated homeostasis between entry and exit of
HDL particles into and from the arterial wall, respectively, is indicated by the
enrichment of modified and dysfunctional HDLs and apoA-I in atherosclerotic
lesions (DiDonato et al. 2013, 2014; Huang et al. 2014).
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4.3.4 Delivery of Cholesterol to the Liver and Intestine
After having left the arterial wall and entered the circulation, the HDL particles
transport the cholesterol either directly or indirectly via apoB-containing
lipoproteins to the liver for either secretion into bile or for de novo assembly of
lipoproteins. The first direct way by which HDL can deliver cholesterol to the liver
is via SR-BI, a cell surface receptor that binds HDLs and mediates the selective
uptake of HDL-associated cholesteryl esters and the subsequent resecretion of
cholesteryl ester-poor HDLs (Acton et al. 1996). Secondly, HDL particles can be
taken up from the circulation by the liver via HDL holoparticle endocytosis (i.e.,
uptake of the whole HDL particle). The binding of apoA-I to the ectopic β-chain of
F0F1 ATPase on hepatocytes triggers extracellular production of ADP, which in
turn acts on the P2Y13 receptor to stimulate HDL holoparticle endocytosis
(Martinez et al. 2003; Jacquet et al. 2005). In humans, the major fraction of the
cholesteryl esters in HDL particles are shuttled via the action of CETP to apoB-
containing lipoproteins (Charles and Kane 2012). These cholesteryl esters
originating from HDLs are internalized as part of apoB-containing lipoproteins
by hepatic LDL receptors. Following hepatic uptake, HDL-derived cholesterol is, at
least in part, targeted for fecal excretion via the biliary route (Lewis and Rader
2005; Nijstad et al. 2011). Hepatic cholesterol can either be secreted directly in the
free form into the bile by the ABCG5/G8 heterodimer or alternatively be converted
by cholesterol 7α-hydroxylase (CYP7A1) and other enzymes into bile acids for
hepatic excretion via the bile salt export pump (BSEP) (Dikkers and Tietge 2010).
Secretion into bile enables cholesterol to move from the hepatocyte to the intestinal
lumen for final excretion via the stool. This major HDL-driven pathway to elimi-
nate atherogenic cholesterol from the body is also known as reverse cholesterol
transport (Annema and Tietge 2012). Although reverse cholesterol transport from
plaque macrophages to feces only represents a very small proportion of the total
reverse cholesterol transport flux from peripheral tissues, it is key component of the
reverse transport potentially capable of initiating and maintaining the regression of
atherosclerosis (Lee-Rueckert et al. 2013).
5 Atherothrombosis
The most important mechanism of acute coronary syndromes, i.e., unstable angina,
acute myocardial infarction, and sudden cardiac death, is rupture or erosion of a
coronary atheroma (Libby 2013b). The risk of atheromatous rupture or erosion
appears to critically depend on both the cellular and extracellular compositions of
the atheroma. The superficial layer of an atheroma separating a necrotic lipid core
from the circulating blood is called the “fibrous cap”. Although a cap usually contains
foam cells, its critical components are VSMCs, which synthesize and secrete collagen
and other components of the extracellular matrix. It is current understanding that the
cap is thinning as the necrotic lipid core is growing. Whether the thinning is a
response to the enlargement of the necrotic core, or whether thinning is an indepen-
dent process and just allows the core to expand, has not been established.
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As expected, a lesion with a thick fibrous cap and a small lipid core is stable,
whereas a lesion with a thin fibrous cap and a large lipid core is unstable and prone
to rupture. Indeed, it is now well recognized that acute coronary syndromes most
commonly result from rupture of a thin-cap fibroatheroma (TCFA), which is
characterized by a large necrotic core with an overlying thin fibrous cap measuring
less than 65 μm (Sakakura et al. 2013; Fujii et al. 2013).
Provided a stable lesion with a thick fibrous cap causes significant stenosis of the
arterial lumen, and turbulent flow conditions are created, some endothelial cells
may detach, that is, the plaque surface becomes eroded (Libby 1995; Farb
et al. 1996). Apoptosis of endothelial cells also leads to endothelial denudation,
i.e., to plaque erosion when, for example, subendothelial mast cells degrade the
basement membrane of endothelial cells (Durand et al. 2004; Mayranpaa
et al. 2006). The exposed subendothelial structures are prothrombotic and a
platelet-rich thrombus is formed locally. Since the activated platelets secrete
platelet-derived growth factor which stimulates SMCs to divide and generate
extracellular matrix, a neointima is formed at the site of erosion. This is one
mechanism by which the fibrotic cap of a stenosing plaque becomes thicker and
the plaque grows into the lumen and so aggravates the local stenosis.
When an unstable TCFA ruptures, the flowing blood becomes exposed to the
necrotic lipid core. The various components of the core, notably tissue factor
released by macrophages, apoptotic bodies, remnants of dead cells, and extracellu-
larly located lipids, all are contributing to the strong thrombogenic response usually
associated with a plaque rupture (Fuster et al. 2005; Corti et al. 2003). Thus, the
platelet-rich arterial thrombus growing at the site of plaque rupture easily becomes
occlusive, even if the plaque only had caused a mild stenosis which was hemody-
namically nonsignificant.
In view of the importance of the thickness of collagen-rich matrix of the fibrous
cap in determining plaque stability and instability, it is essential to understand the
factors that may regulate its thickness. Regarding such regulation, two related
observations made in advanced human atherosclerotic plaques are of prime impor-
tance. First, irrespective of the structure of an atherosclerotic plaque, the actual site
of atheromatous ulceration with ensuing local formation of a platelet-rich thrombus
is characterized by an inflammatory process (van der Wal et al. 1994). Thus,
atheromatous coronary and carotid ulcerations have invariably shown the presence
of inflammatory cell infiltrates, composed of macrophages, T cells, and mast cells
(Kovanen et al. 1995; Bui et al. 2009). When compared with the evolving athero-
sclerotic plaques, which contain inflammatory cell infiltrates, composed of various
subsets of macrophages and T cells and also of mast cells and neutrophils
(Woollard 2013), the vulnerable plaques appear to be equally, if not even more
immunologically, active. The second critical aspect of a vulnerable atherosclerotic
plaque is the fact that SMCs are dying in their fibrous caps (Bennett 1999).
Fundamentally, the various activities of SMCs tend to thicken the cap, while
those of the inflammatory cells tend to oppose them. The net production of matrix
components depends on the number of the matrix-producing SMCs and the ability
of the individual cells to produce such components. The number of SMCs depends
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on the balance of cell replication and cell death. In human atherosclerotic plaques,
the infiltrating lymphocytes are of the Th1 subpopulation of CD4+ cells and the
pro-inflammatory Th1-derived cytokines, notably interferon-gamma, dominate
(Hansson 2005). This cytokine is able to inhibit the capacity of SMCs to produce
collagen (Libby 1995) and together with TNFα and interleukin-1β (IL-1β) contrib-
ute to their apoptotic death. Thus, activation of Th1 cells, together with IL-1-
β-producing macrophages and TNFα-producing mast cells within the cap of an
atheroma, could lower the local rate of collagen production by lowering the number
of SMCs and by inhibiting the rate of synthesis in those SMCs that survive
(Kaartinen et al. 1996). Importantly, the fibrous caps often contain cholesterol
crystals, which have the potential to activate the NLRP3 inflammasome in
macrophages and so trigger release of IL-1β from the macrophages (Rajamaki
et al. 2010; Duewell et al. 2010). Since it is unlikely that HDLs are capable of
removing crystalline cholesterol from the intima, the crystals, once formed, may
permanently stimulate cap macrophages to secrete IL-1β and so contribute to the
ongoing cap thinning.
The various components of the extracellular matrix are degraded by members of
the superfamily of matrix metalloproteinases (MMPs) primarily produced by the
macrophages of the caps (Newby 2005). For the MMPs to become active, they need
to be proteolytically activated. Among the proteolytic enzymes capable of
activating plaque MMPs are plasmin, chymase, and tryptase, the two latter ones
being neutral proteases secreted by activated mast cells in atherosclerotic lesions
(Johnson et al. 1998). Once activated, interstitial collagenase, MMP-1, can degrade
the otherwise protease-resistant fibrillar collagen fibers into fragments, and another
member of the family, MMP-9, can break collagen fragments further. Importantly,
stromelysin, MMP-3, has a broad spectrum and can degrade other components of
the extracellular matrix as well, including proteoglycans and elastin (Libby 2013a).
Cathepsins are another group of enzymes capable of effectively degrading the
various components of the fibrous cap (Fonovic and Turk 2014). Thus, the presence
of inflammatory cells in the caps of advanced plaques tends to render the plaque
unstable and prone to rupture by both decreasing the production and increasing the
degradation of the extracellular matrix of the fibrous cap.
5.1 Effects of HDLs on Smooth Muscle Cells
VSCMs can indirectly influence the development of atherosclerosis by the secretion
of growth factors and vasoactive agents, and the protective effects of HDLs on
atherosclerotic lesion formation might, at least partly, be related to their impact on
the secretory function of VSMCs. Exposure of aortic SMCs to mildly oxidized LDLs
enhanced the production and release of platelet-derived growth factor and basic
fibroblast growth factor, while addition of HDLs abolished the stimulatory effect of
oxidized LDLs on growth factor secretion by these VSMCs (Cucina et al. 1998,
2006). Conversely, treatment of rabbit SMCs in culture with HDLs potentiated the
synthesis of the vasodilator prostacyclin via a mechanism involving MAP kinase
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kinase signaling and increased cyclooxygenase-2 expression (Vinals et al. 1997,
1999). VSMCs are also considered to protect the atherosclerotic plaque against
destabilization and rupture. In this respect, HDLs regulate both the proliferation and
migration of VSMCs. Nofer and colleagues showed that HDLs accelerate prolifer-
ation of VSMCs by driving the cell cycle forward in the G1 phase via cyclin
D1-induced phosphorylation of pRb (Nofer et al. 2001a). Elevated cyclin D1
expression in VSMCs in response to treatment with HDLs in turn relies on activa-
tion of the Raf/MEK/ERK signal transduction pathway (Nofer et al. 2001a). On the
other hand, the platelet-derived growth factor-mediated migration of VCMCs is
limited by HDLs through the interaction of HDL-bound S1P with the S1P2 receptor
(Tamama et al. 2005). Finally, HDLs were found to suppress inflammatory
responses in VSMCs. Oxidized LDLs, via formation of ROS, induced NF-κβ
activation in cultured VSMCs, while their pretreatment with HDLs inhibited the
intracellular rise in ROS and the subsequent upregulation of NF-κβ elicited by the
oxidized LDLs (Robbesyn et al. 2003).
5.2 Antithrombotic Effects of HDLs
5.2.1 HDLs and Platelets
The majority of acute coronary syndromes are caused by the rupture of an athero-
sclerotic plaque in a coronary artery and subsequent formation of an occlusive
coronary thrombus. There appears to be a relationship between plasma HDLs and
the thrombogenic potential of blood, as evidenced by the fact that the total throm-
bus area in an ex vivo flow chamber model for coronary thrombosis was lower in
human subjects with higher HDL cholesterol levels (Naqvi et al. 1999). HDLs have
several favorable effects on platelets that might explain its interference with
thrombus formation in the coronary vasculature. First, it has been reported that
HDLs can block the activation and aggregation of platelets. In a small clinical trail,
13 patients with type 2 diabetes mellitus were randomized to a single infusion of
rHDLs (CSL-111) or placebo (Calkin et al. 2009). Study results established that a
40 % increase in HDL cholesterol levels in patients with type 2 diabetes mellitus
was associated with a 50–75 % reduction in platelet aggregation (Calkin
et al. 2009). A similar decrease in the aggregation of platelets was observed when
isolated human platelets were incubated with rHDLs or native HDLs in vitro
(Calkin et al. 2009; Nofer et al. 1998; Badrnya et al. 2013). Native HDLs and
rHDLs not only modulate platelet aggregation but also prevent platelet degranula-
tion and spreading as well as adhesion of platelets to fibrinogen (Calkin et al. 2009;
Nofer et al. 1998; Badrnya et al. 2013). In addition, rHDLs limited the
incorporation of platelets in growing thrombi under flow conditions in vitro (Calkin
et al. 2009). The ability of HDLs to block platelet aggregation was proposed to be
due to a reduction in the availability of the second messengers 1,2-diacylglycerol
and inositol 1,4,5-trisphosphate, a decreased mobilization of intracellular calcium,
activation of protein kinase C, and elevated Na+/H+ exchange (Nofer et al. 1996;
1998). The role of SR-BI for the anti-aggregatory effect of HDLs is controversial.
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One study reported that inhibition of platelet reactivity by HDLs results from
cholesterol depletion in lipid rafts but that this is independent of ABCG1 and
SR-BI (Calkin et al. 2009). In contrast, Brodde et al. found that SR-BI is the
receptor responsible for binding of HDL to platelets and that HDLs are no longer
able to attenuate thrombin-induced adhesion of platelets to fibrinogen when using
platelets isolated from SR-BI knockout mice (Brodde et al. 2011). The inhibitory
activity of HDLs on platelets is mimicked by soybean phosphocholine (Calkin
et al. 2009) and phosphatidylserine-containing liposomes (Brodde et al. 2011),
underlining the importance of the phospholipid component in this antithrombotic
function of HDLs. As a final point, HDLs may regulate the platelet coagulant
activity by reducing the synthesis of platelet-activating factor in endothelial cells
(Sugatani et al. 1996).
Another step of the arterial atherothrombotic process in which HDLs may
interfere is the production of platelets from bone marrow megakaryocyte progenitor
cells. In vitro experiments have revealed that rHDLs promote the removal of
cholesterol from megakaryocyte progenitor cells in an ABCG4-dependent fashion,
thereby decreasing cellular proliferation (Murphy et al. 2013). Consistent with
these observations, intravenous administration of rHDLs resulted in a decrease in
the amount of bone marrow megakaryocyte progenitor cells and concomitantly
reduced circulating platelets in Ldlr/ mice transplanted with wild-type bone
marrow, while rHDLs lost their effects on bone marrow megakaryocyte progenitor
cells and platelet numbers when injected into Ldlr/ mice that were transplanted
with ABCG4-deficient bone marrow (Murphy et al. 2013). A small placebo-
controlled clinical study demonstrated that a single injection of rHDLs significantly
reduced platelet counts in patients with peripheral vascular disease (Murphy
et al. 2013). The importance of deregulation of cholesterol homeostasis in mega-
karyocyte progenitor cells for atherothrombosis was supported by evidence that
selective disruption of ABCG4 in bone marrow cells of LDL receptor knockout
mice accelerated the progression of atherosclerotic lesion formation and was
associated with marked thrombocytosis and an increased tendency to develop
arterial thrombosis (Murphy et al. 2013).
5.2.2 HDLs and Coagulation
Various publications have described an impact of HDLs on the extrinsic coagula-
tion pathway that might result in a decreased tendency for thrombosis. Inhibition of
the catalytic activity of the tissue factor–factor VIIA complex by HDLs has been
shown to impede the activation of the procoagulant factor X (Carson 1981). Besides
direct inactivation of tissue factor and factor Va, HDLs are able to modulate the
tissue factor-activated coagulation cascade by downregulating tissue factor expres-
sion in thrombin-stimulated endothelial cells through suppression of RhoA and
induction of PI3K (Viswambharan et al. 2004). In addition, incorporation of anionic
phospholipids into apoA-I-containing rHDL particles resulted in the loss of their
procoagulant properties, revealing that, by scavenging anionic phospholipids,
apoA-I may control blood coagulation (Oslakovic et al. 2009). HDLs have also
been shown to promote the ability of the anticoagulant activated protein C and its
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cofactor protein S to cause inactivation of factor Va through Arg306 cleavage, and in
normal healthy subjects, plasma levels of apoA-I were positively correlated with
the anticoagulant potency of activated protein C and protein S in a prothrombin-
time clotting assay (Griffin et al. 1999). Of note, these findings were later
questioned by another study revealing that the previously observed capacity of
the HDL fraction to boost the activated protein C system was not an actual property
of HDLs, but instead was due to co-isolation of anionic phospholipid membranes
with the HDL fraction during ultracentrifugation (Oslakovic et al. 2010).
6 Myocardial Injury
The main pathophysiological manifestation of coronary heart disease is myocardial
damage due to ischemia–reperfusion. It has been postulated that HDLs can provide
protection against myocardial injury following ischemia–reperfusion. In an in vivo
murine ischemia–reperfusion model, it was found that the infarcted area was
decreased when mice were treated 30 min before ischemia–reperfusion with either
human HDLs or S1P (Theilmeier et al. 2006). In this regard, HDL or S1P injection
mitigated the inflammatory response to ischemia–reperfusion as manifested by a
lower accumulation of leukocytes in the infarcted area (Theilmeier et al. 2006).
Furthermore, cardiomyocytes were better able to resist ischemia–reperfusion-
induced apoptosis in the presence of HDLs or S1P (Theilmeier et al. 2006), poten-
tially due to a higher tolerance of HDL-treated cardiomyocytes to hypoxia-induced
opening of the mitochondrial permeability transition pore (Frias et al. 2013). S1P3
was identified as the receptor responsible for the beneficial effect of HDLs and S1P
on reperfusion injury (Theilmeier et al. 2006). The finding that HDLs ameliorate
myocardial ischemia–reperfusion damage has subsequently been confirmed and
extended by others. Ex vivo exposure of isolated hearts from wild-type mice to
HDLs provided dose-dependent cardioprotection from reperfusion injury (Frias
et al. 2013). On the other hand, HDL-mediated protection of isolated hearts or
cardiomyocytes against hypoxia was lost in mice deficient in tumor necrosis factor
and in mice with cardiomyocyte-restricted knockout of signal transducer and
activator of transcription 3 (STAT3) (Frias et al. 2013), suggesting a role for the
survivor activating factor enhancement pathway which is initiated by tumor necro-
sis factor and involves activation of STAT3. In another study, HDL cholesterol
levels were raised in LDL receptor-deficient mice using adenovirus-mediated gene
transfer of human apoA-I (Gordts et al. 2013). After induction of myocardial
infarction by permanent ligation of the left anterior descending coronary artery,
mice that were injected with an adenovirus expressing human apoA-I exhibited a
higher survival rate, reduced infarct expansion, attenuated dilatation of the left
ventricle, as well as improved systolic and diastolic cardiac function when com-
pared with controls (Gordts et al. 2013).
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Conclusions
HDL particles exert many effects which may help either to protect arteries from
the development, progression, and complication of atherosclerosis or even
facilitate repair and regression of lesions. Nevertheless, HDL has not yet been
successfully exploited for preventive or curative therapy of cardiovascular
diseases. One potential reason for this shortfall is the structural and functional
complexity of HDL particles which is further increased in several inflammatory
conditions including CAD itself and which is not discerned by the biomarker
HDL cholesterol. Moreover, the relative importance of the many physiological
and pathological activities of normal and dysfunctional HDL, respectively, for
the pathogenesis of atherosclerosis is unknown. The elucidation of structure–
function relationships of HDL-associated molecules is essential to exploit HDL
for the development of anti-atherogenic drugs as well as of diagnostic
biomarkers for the identification, personalized treatment stratification, and mon-
itoring of patients at increased cardiovascular risk. In addition to the metabolism
of HDL or its anti-atherogenic molecules, also the cellular pathways positively
regulated by HDL are interesting targets for anti-atherosclerotic therapies.
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